Breaking News Instant updates and real-time market news.

AAAP

Advanced Accelerator

$59.76

1.46 (2.50%)

, NVS

Novartis

$84.57

-0.67 (-0.79%)

08:30
09/28/17
09/28
08:30
09/28/17
08:30

Novartis considering deal to buy Advanced Accelerator, Bloomberg says

Novartis (NVS) has approached Advanced Accelerator Applications (AAAP) about a deal and held talks about a potential acquisition of the radiopharmaceutical company, according to Bloomberg, citing people familiar with the matter. Reference Link

AAAP

Advanced Accelerator

$59.76

1.46 (2.50%)

NVS

Novartis

$84.57

-0.67 (-0.79%)

  • 08

    Nov

  • 26

    Jan

  • 17

    May

AAAP Advanced Accelerator
$59.76

1.46 (2.50%)

06/15/17
JPMS
06/15/17
INITIATION
Target $50
JPMS
Overweight
Advanced Accelerator initiated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye started Advanced Accelerator Applications with an Overweight rating and $50 price target. The analyst sees "compelling efficacy" for the company's key product Lutathera in somatostatin receptor positive midgut neuroendocrine tumors. She sees a $600M peak sales opportunity for the drug.
07/27/17
JMPS
07/27/17
UPGRADE
JMPS
Outperform
Advanced Accelerator upgraded to Outperform at JMP Securities
07/27/17
JMPS
07/27/17
UPGRADE
Target $69
JMPS
Outperform
Follow-up: Advanced Accelerator upgraded to Outperform at JMP Securities
As previously reported, JMP Securities upgraded Advanced Accelerator to Outperform from Market Perform with a $69 price target citing the positive CHMP opinion for the marketing authorization of Lutathera for gastroenteropancreatic neuroendocrine tumors.
07/28/17
ADAM
07/28/17
NO CHANGE
Target $60
ADAM
Buy
Advanced Accelerator price target raised to $60 from $47 at Canaccord
Canaccord analyst John Newman raised his price target on Advanced Accelerator to $60 from $47 to reflect a higher pricing estimate for Lutathera and higher confidence in U.S. approval. Newman reiterated his Buy rating on Advanced Accelerator shares.
NVS Novartis
$84.57

-0.67 (-0.79%)

07/26/17
07/26/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Chipotle (CMG) upgraded to Hold from Underperform at Jefferies with analyst Andy Barish saying the current valuation and consensus estimates "now reflect the reality" of Chipotle's path to recovery. 2. Biogen (BIIB) upgraded to Buy from Neutral at Goldman Sachs with analyst Terence Flynn saying the company's balance sheet is under-levered, which provides flexibility, while Aducanumab provides Alzheimer's optionality. 3. DSW (DSW) upgraded to Outperform from Neutral at Wedbush with the firm saying it is more confident that second quarter results will beat expectations and that the company will reiterate its full-year guidance after conducting checks and speaking with the company. 4. Electronic Arts (EA) upgraded to Buy from Neutral at BofA/Merrill with analyst Justin Post citing a strong fiscal 2019 outlook. 5. Novartis (NVS) upgraded to Overweight from Underweight at Morgan Stanley with analyst Vincent Meunier upgrading the company two notches to Overweight from Underweight following a "massive" reset in consensus expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
08/31/17
MSCO
08/31/17
NO CHANGE
MSCO
Equal Weight
Gilead response to Kymriah pricing 'confusing,' says Morgan Stanley
Morgan Stanley analyst Matthew Harrison said Novartis' (NVS) pricing of its Kymriah therapy at $475,000 gross puts "some slight pressure" on his model for Juno Therapeutics (JUNO), though he doesn't see it as "that far out of line" with his expectations. While he said it makes sense that Juno saw some pressure yesterday after the pricing news and that bluebird bio (BLUE) closed the gap with Juno, he called Gilead's (GILD) strength yesterday "a bit more confounding" given that Gilead is focused on the same indication as Juno. However, initial DLBCL sales in 2018 for both Gilead and Novartis are likely to drive sentiment, so greater clarity won't be seen until then, added Harrison, who keeps an Equal Weight rating on Juno shares.

TODAY'S FREE FLY STORIES

07:51
02/22/18
02/22
07:51
02/22/18
07:51
General news
Futures pointing to higher open »

Stock futures have…

07:51
02/22/18
02/22
07:51
02/22/18
07:51
Conference/Events
The FCC to hold a commission meeting »

Open Commission Meeting…

07:50
02/22/18
02/22
07:50
02/22/18
07:50
Conference/Events
Federal Reserve Bank of New York President speaks at press briefing »

New York Federal Reserve…

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

07:49
02/22/18
02/22
07:49
02/22/18
07:49
Recommendations
Stamps.com analyst commentary  »

Stamps.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 23

    May

LNKD

Acquired by MSFT

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Conference/Events
Detroit Economic Club to hold a breakfast meeting »

Brenda Meller, Owner and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MCS

Marcus

$26.10

1 (3.98%)

07:48
02/22/18
02/22
07:48
02/22/18
07:48
Earnings
Marcus reports Q4 EPS $1.21, consensus 38c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    May

PHX

Panhandle Oil & Gas

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Initiation
Panhandle Oil & Gas initiated  »

Panhandle Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 11

    Mar

CRM

Salesforce

$114.48

0.13 (0.11%)

07:47
02/22/18
02/22
07:47
02/22/18
07:47
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 28

    Feb

07:46
02/22/18
02/22
07:46
02/22/18
07:46
Conference/Events
FDA to co-host a workshop »

The FDA, American…

MLNX

Mellanox

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Recommendations
Mellanox analyst commentary  »

Mellanox price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

RDHL

RedHill Biopharma

$6.26

0.05 (0.81%)

07:44
02/22/18
02/22
07:44
02/22/18
07:44
Earnings
RedHill Biopharma reports Q4 EPS (26c), consensus (60c) »

Reports Q4 revenue $2M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 11

    Mar

07:43
02/22/18
02/22
07:43
02/22/18
07:43
Conference/Events
JPMorgan to hold a conference »

Korea Conference will be…

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees FY18 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Conference/Events
Deutsche Bank to hold a conference »

Indonesia Corporate Days…

ROKU

Roku

$51.10

-0.08 (-0.16%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Recommendations
Roku analyst commentary  »

Roku price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 21

    Mar

HSC

Harsco

$16.75

0.45 (2.76%)

07:42
02/22/18
02/22
07:42
02/22/18
07:42
Earnings
Breaking Earnings news story on Harsco »

Harsco sees Q1 adj. EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

AKBA

Akebia

$14.31

0.69 (5.07%)

, CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

07:41
02/22/18
02/22
07:41
02/22/18
07:41
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

AKBA

Akebia

$14.31

0.69 (5.07%)

CRSP

Crispr Therapeutics

$41.16

-0.45 (-1.08%)

RDUS

Radius Health

$37.71

-0.51 (-1.33%)

TYME

Tyme Technologies

$3.37

-0.06 (-1.75%)

HCA

HCA Healthcare

$100.35

-0.65 (-0.64%)

ARAY

Accuray

MDRX

Allscripts

$13.57

0.335 (2.53%)

ABEO

Abeona Therapeutics

$11.70

0.1 (0.86%)

SGEN

Seattle Genetics

$54.11

-0.05 (-0.09%)

INSY

Insys Therapeutics

$7.93

0.34 (4.48%)

SPPI

Spectrum

$20.51

0.21 (1.03%)

SPH

Suburban Propane

$24.10

-0.2 (-0.82%)

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

DEPO

Depomed

$7.46

0.07 (0.95%)

KTWO

K2M Group

$19.09

-0.01 (-0.05%)

INOV

Inovalon

$11.68

-1.025 (-8.07%)

IMMU

Immunomedics

$16.38

0.16 (0.99%)

OVID

Ovid Therapeutics

$6.83

-0.2 (-2.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 11

    Mar

  • 14

    Mar

  • 01

    May

  • 03

    May

  • 22

    Feb

HSC

Harsco

$16.75

0.45 (2.76%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Earnings
Harsco reports Q4 EPS ex-items 20c, consensus 14c »

Reports Q4 revenue $455M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

WPC

W.P. Carey

$59.53

-0.73 (-1.21%)

07:40
02/22/18
02/22
07:40
02/22/18
07:40
Hot Stocks
W.P. Carey enters into 18-year triple net lease with Astellas Institute »

W. P. Carey has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

07:40
02/22/18
02/22
07:40
02/22/18
07:40
General news
Fed's Quarles anticipates further gradual tightening »

Fed's Quarles…

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Earnings
Gibraltar Industries sees FY18 adjusted EPS $1.96-$2.08, consensus $1.81 »

Gibraltar is providing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$109.06

-1.92 (-1.73%)

07:39
02/22/18
02/22
07:39
02/22/18
07:39
Recommendations
Chevron analyst commentary  »

Chevron weakness a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRC

Brady

$38.05

0.1 (0.26%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Brady reports Q2 EPS 8c, may not be compared to consensus 44c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ROCK

Gibraltar Industries

$31.75

0.35 (1.11%)

07:38
02/22/18
02/22
07:38
02/22/18
07:38
Earnings
Gibraltar Industries sees Q1 adjusted EPS 23c-28c, one est. 30c »

For Q1, the company is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$53.99

-0.81 (-1.48%)

07:37
02/22/18
02/22
07:37
02/22/18
07:37
Earnings
Welltower sees 2018 normalized FFO $3.95-$4.05, consensus $4.20 »

Expects average blended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.